MINNEAPOLIS–(BUSINESS
WIRE)–Today, Medtronic, Inc. announced U.S. Food and Drug
Administration (FDA) approval and U.S. market launch of the first-of-its-kind
mySentry™ Remote Glucose Monitor, which allows a parent or caregiver to monitor
from another room a patients MiniMed Paradigm® REAL-Time Revel™ System. The
remote glucose monitor also marks the launch of a new category of Connected
Care solutions that will provide people with diabetes and their caregivers
convenient options to access their diabetes management information.
mySentry allows caregivers to see real-time insulin pump
status and glucose trends, as well as hear alerts and alarms, at their bedside
while an adult or child with diabetes sleeps in his or her own room. This could
be especially useful for parents, who could be alerted through a predictive
alarm in the middle of the night if their childs glucose levels are falling,
allowing them to take action to prevent an episode of low blood sugar
(hypoglycemia). For a caregiver of someone with type 1 diabetes, nighttime
hypoglycemia (low blood sugar) represents one of their greatest concerns.
“Many of the parents of our patients wake up a couple of
times every night to check their childs blood sugar level and even that may
not be enough to prevent episodes of severe hypoglycemia,” said William
Tamborlane, M.D., Chief of Pediatric Endocrinology and Deputy Director of the
Yale Center for Clinical Investigation. “Advances in continuous glucose
monitoring, including remote monitoring like mySentry, have given parents an
added level of protection from dangerous nighttime hypoglycemia occurring in
their sleeping child, as well as a means to improve their quality of life.”
An estimated 75 percent of all episodes of severe
hypoglycemia in children occur at night1. By alerting a parent or caregiver to
an alarm, mySentry may provide added nighttime protection.
“Were excited to bring this new innovation to market that
could give caregivers greater peace of mind. The mySentry Remote Glucose
Monitor is the first step toward our vision to develop an entire category of
Connected Care products that help people more proactively manage their diabetes
by making it easier and more convenient to access the wealth of information
captured by our integrated insulin pump and continuous glucose monitoring (CGM)
system,” said Greg Meehan, Vice President and General Manager of the Continuous
Glucose Monitoring business at Medtronic.
mySentry is used in conjunction with the MiniMed Paradigm®
REAL-Time Revel™ System, an insulin pump with built-in continuous glucose
monitoring. mySentry can be placed in the bedroom or in any room throughout the
house so all important information is just a glance away. mySentry provides
flexibility and a wide range of uses including displaying all of the alerts and
alarms available on the Paradigm Revel insulin pump: predictive alerts,
continuous glucose monitoring (CGM) graph, insulin pump battery life, amount of
insulin remaining, and time until the next glucose sensor calibration.
Medtronic is committed to working with health insurance
providers to ensure access to and reimbursement for the product. More
information is available at www.medtronicdiabetes.com/mysentry.
About the Diabetes Business at Medtronic
The Diabetes business at Medtronic (www.medtronicdiabetes.com) is the world leader in advanced
diabetes management solutions, including integrated diabetes management
systems, insulin pump therapy, continuous glucose monitoring systems and
therapy management software, as well as world-class, 24/7 expert consumer and
professional service and support.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical
technology – alleviating pain, restoring health and extending life for millions
of people around the world.
1 Ahmet A, Dagneais S, Barrowman NJ, et al. Prevalence of
Nocturnal Hypoglycemia in Pediatric Type 1 Diabetes: A Pilot Study Using
Continuous Glucose Monitoring. J Pediatrics,159:2,297-302.
Posted by Sean Fenske, Editor-in-Chief, MDT
